HC Wainwright Issues Optimistic Forecast for Myomo Earnings

Myomo, Inc. (NYSEAMERICAN:MYO) – Stock analysts at HC Wainwright boosted their Q1 2025 earnings per share estimates for shares of Myomo in a report issued on Wednesday, March 12th. HC Wainwright analyst S. Lee now anticipates that the company will post earnings of ($0.09) per share for the quarter, up from their previous estimate of ($0.11). HC Wainwright currently has a “Buy” rating and a $9.50 target price on the stock. The consensus estimate for Myomo’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Myomo’s Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.04) EPS, Q4 2025 earnings at $0.04 EPS, FY2025 earnings at ($0.13) EPS and FY2027 earnings at $0.20 EPS.

MYO has been the topic of several other reports. Alliance Global Partners reissued a “buy” rating on shares of Myomo in a research note on Tuesday, March 11th. Craig Hallum boosted their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, March 11th. Finally, Ascendiant Capital Markets increased their price target on shares of Myomo from $9.00 to $11.00 and gave the stock a “buy” rating in a report on Monday. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Myomo currently has a consensus rating of “Buy” and a consensus target price of $9.75.

Myomo Price Performance

Shares of MYO opened at $5.44 on Monday. Myomo has a fifty-two week low of $2.51 and a fifty-two week high of $7.17. The stock has a market cap of $164.56 million, a PE ratio of -23.65 and a beta of 1.68.

Insider Activity at Myomo

In other news, Director Thomas F. Kirk purchased 7,400 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were bought at an average cost of $5.00 per share, with a total value of $37,000.00. Following the purchase, the director now directly owns 255,933 shares of the company’s stock, valued at approximately $1,279,665. This trade represents a 2.98 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Micah Mitchell sold 48,000 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $5.16, for a total transaction of $247,680.00. Following the completion of the transaction, the insider now directly owns 140,572 shares of the company’s stock, valued at approximately $725,351.52. This represents a 25.45 % decrease in their position. The disclosure for this sale can be found here. 4.54% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MYO. GSA Capital Partners LLP grew its stake in shares of Myomo by 60.8% during the 3rd quarter. GSA Capital Partners LLP now owns 103,342 shares of the company’s stock valued at $414,000 after buying an additional 39,085 shares during the period. Stonepine Capital Management LLC purchased a new position in shares of Myomo in the 3rd quarter worth $401,000. Jane Street Group LLC acquired a new position in Myomo in the third quarter valued at $65,000. XTX Topco Ltd purchased a new stake in Myomo during the third quarter valued at about $149,000. Finally, Barclays PLC acquired a new stake in Myomo during the third quarter worth about $36,000. Institutional investors and hedge funds own 44.99% of the company’s stock.

About Myomo

Myomo, Inc, a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, China, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living.